U.S. intelligence officials in late February told senators working on a biotech security bill that Chinese pharmaceutical firm WuXi AppTec had transferred U.S. intellectual property to Beijing without consent, according to two sources.

The U.S. government is concerned that certain Chinese biotech companies are contributing technology or research and development for use by China’s military, and the proposed legislation would restrict U.S. government funds going to those Chinese companies.

The classified briefing to about a dozen senators was led by the FBI, the State Department and the Office of the Director of National Intelligence. Those officials said that WuXi AppTec and other Chinese entities had engaged in activity in the U.S. contrary to U.S. national security interests, the sources said on condition of anonymity.